Imperial College London
Alternate

DrSarahBlagden

Faculty of Medicine, Department of Surgery & Cancer

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

s.blagden

 
 
//

Location

 

Cyclotron buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Blagden:2014:10.1158/1078-0432.CCR-14-1315,
author = {Blagden, S and Olmin, A and Josephs, D and Stavraka, C and Zivi, A and Pinato, DJ and Anthoney, A and Decordova, S and Swales, K and Riisnaes, R and Pope, L and Noguchi, K and Shiokawa, R and Inatani, M and Prince, J and Jones, K and Twelves, C and Spicer, J and Banerji, U},
doi = {10.1158/1078-0432.CCR-14-1315},
journal = {CLINICAL CANCER RESEARCH},
pages = {5908--5917},
title = {First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer},
url = {http://dx.doi.org/10.1158/1078-0432.CCR-14-1315},
volume = {20},
year = {2014}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AU  - Blagden,S
AU  - Olmin,A
AU  - Josephs,D
AU  - Stavraka,C
AU  - Zivi,A
AU  - Pinato,DJ
AU  - Anthoney,A
AU  - Decordova,S
AU  - Swales,K
AU  - Riisnaes,R
AU  - Pope,L
AU  - Noguchi,K
AU  - Shiokawa,R
AU  - Inatani,M
AU  - Prince,J
AU  - Jones,K
AU  - Twelves,C
AU  - Spicer,J
AU  - Banerji,U
DO  - 10.1158/1078-0432.CCR-14-1315
EP  - 5917
PY  - 2014///
SN  - 1078-0432
SP  - 5908
TI  - First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
T2  - CLINICAL CANCER RESEARCH
UR  - http://dx.doi.org/10.1158/1078-0432.CCR-14-1315
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346417400008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL  - 20
ER  -
Download